Celltrion took the top place in the domestic brand reputation list of pharmaceutical companies in January. Following Celltrion’s lead was Samsung Biologics, which ranked first in December, and the third place went to Celltrion Healthcare.
The Korea Corporate Reputation Research Institute (KCRRI) analyzed nearly 70,795,986 big data of 116 domestic listed pharmaceuticals from Dec 28. to Jan. 29 and released the result on Thursday. The institute gets brand reputation index (BRI) through dividing consumer activity-related big data on a brand by participation index (PI), communication index (CMI), community index (CI), and market index (MI).
Celltrion took the first place with a PI of 2,274,300, CMI of 1,516,055, CI of 412,805 and MI of 4,453,835, scoring 8,656,994 in total BRI, recording a 10.25 percent increase from last month.
Samsung BioLogics, which ranked the second, recorded BRI of 8,316,223 by getting PI of 82,494, CMI of 42,506, CI of 51,456, and MI of 6.655,866.
Celltrion Healthcare and Chong Kun Dang Pharmaceutical ranked third and fourth, respectively, with total BRI of 33,394,944 and 2,254,433. Celltrion Pharmaceutical ranked fifth with BRI of 886,855, an increase of 120.19 percent from the previous month, putting all “Celltrion trio” in the top five places.
"Celltrion brand has production facilities that can make 140,000 liters of animal cell culture protein-based pharmaceutical products, which is the largest in Asia," Gu Chang-hwan, director of the institute said. "We also evaluated it highly that the company plans to build a third plant by taking into account future development demands and schedules."
<© Korea Biomedical Review, All rights reserved.>